Altogether, the NLRP3 inflammasome signatures in myeloid cells may represent a predictive biomarker for COVID-19 development and patient outcome and provide important guidance for therapeutic decisions involving immunoregulatory agents. The gene discussed is NLRP3; the disease is COVID-19.